Depression in Parkinson's disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1)

[1]  R. Watts,et al.  Treatment of depression in Parkinson's disease. , 2004, Parkinsonism & related disorders.

[2]  V. Arango,et al.  Upregulation of CB1 receptors and agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide victims , 2004, Molecular Psychiatry.

[3]  Mahlon R DeLong,et al.  Prevalence, etiology, and treatment of depression in Parkinson’s disease , 2003, Biological Psychiatry.

[4]  J. Hoenicka,et al.  Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients , 2003, Molecular Psychiatry.

[5]  M. Serrano-Dueñas.  [A comparison between low doses of amitriptyline and low doses of fluoxetin used in the control of depression in patients suffering from Parkinson's disease]. , 2002, Revista de neurologia.

[6]  N. Wainwright,et al.  Childhood adversity, gender and depression over the life-course. , 2002, Journal of affective disorders.

[7]  David Robbe,et al.  Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Marsicano,et al.  Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain , 2002, Neuroscience.

[9]  J. Samochowiec,et al.  Association of a CB1 cannabinoid receptor gene (CNR1) polymorphism with severe alcohol dependence. , 2002, Drug and alcohol dependence.

[10]  M. Serrano-Dueñas.  Dosis bajas de amitriptilina frente a dosis bajas de fluoxetina en el tratamiento de la depresiÓn de enfermos con Parkinson , 2002 .

[11]  H Ujike,et al.  CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia , 2002, Molecular Psychiatry.

[12]  M. Parmentier,et al.  Involvement of CB1 cannabinoid receptors in emotional behaviour , 2002, Psychopharmacology.

[13]  J. Brotchie,et al.  Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A pilot study , 2001, Neurology.

[14]  P. Jenner,et al.  Increased cannabinoid CB1 receptor binding and activation of GTP‐binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP‐treated marmosets , 2001, The European journal of neuroscience.

[15]  A. Young,et al.  Emerging targets for the treatment of depressive disorder , 2001, Expert opinion on therapeutic targets.

[16]  N. Hattori,et al.  Parkin and Parkinson's disease , 2001, Current opinion in neurology.

[17]  S. Tsai,et al.  Association study between cannabinoid receptor gene (CNR1) and pathogenesis and psychotic symptoms of mood disorders. , 2001, American journal of medical genetics.

[18]  D. Heller,et al.  The cannabinoid receptor gene (CNR1) is not affected in German i.v. drug users , 2001, Addiction biology.

[19]  N. Wood,et al.  Genetics of Parkinsonism: a review. , 2001, Annals of human genetics.

[20]  J. Jankovic,et al.  Variability and validity of polymorphism association studies in Parkinson’s disease , 2000, Neurology.

[21]  D. Collier,et al.  No association between (AAT)n repeats in the cannabinoid receptor gene (CNR1) and heroin abuse in a Chinese population , 2000, Molecular Psychiatry.

[22]  J. Walker,et al.  Motor actions of cannabinoids in the basal ganglia output nuclei. , 1999, Life sciences.

[23]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[24]  K. Mackie,et al.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system , 1998, Neuroscience.

[25]  C. Aibar-Remon,et al.  [Drug-induced parkinsonism. Clinical aspects compared with Parkinson disease]. , 1998, Revista de neurologia.

[26]  M. Merello,et al.  Depression in classic versus akinetic‐rigid Parkinson's disease , 1998, Movement disorders : official journal of the Movement Disorder Society.

[27]  Cheng‐Huai Lin,et al.  The correlation of depression with functional activity in Parkinson’s disease , 1997, Journal of Neurology.

[28]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[29]  D. Comings,et al.  Cannabinoid receptor gene (CNR1): association with IV drug use , 1997, Molecular Psychiatry.

[30]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[31]  J. Cummings,et al.  The occurrence of depression in Parkinson's disease. A community-based study. , 1996, Archives of neurology.

[32]  D. Comings.  Polygenic inheritance and minisatellites , 1996 .

[33]  L. Chia,et al.  Studies of dementia, depression, electrophysiology and cerebrospinal fluid monoamine metabolites in patients with Parkinson's disease , 1995, Journal of the Neurological Sciences.

[34]  R. Musty,et al.  Relationships between motivation and depression in chronic marijuana users. , 1995, Life sciences.

[35]  E. Dawson.  Identification of a highly polymorphic triplet repeat marker for the brain cannabinoid receptor gene: Use in linkage and association studies of schizophrenia , 1995, Schizophrenia Research.

[36]  H. Mayberg,et al.  Depression in Parkinson's disease: a biochemical and organic viewpoint. , 1995, Advances in neurology.

[37]  R. Murray,et al.  Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder , 1995, Psychiatric genetics.

[38]  V. Kostic,et al.  Effect of age at onset on frequency of depression in Parkinson's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[39]  T. Bonner,et al.  Localization of cannabinoid receptor mRNA in rat brain , 1993, The Journal of comparative neurology.

[40]  D. GiliSaladié,et al.  [Depression in Parkinson's disease and its relation to the cognitive and motor manifestations]. , 1992 .

[41]  G. Schroth,et al.  Mapping Z-DNA in the human genome. Computer-aided mapping reveals a nonrandom distribution of potential Z-DNA-forming sequences in human genes. , 1992, The Journal of biological chemistry.

[42]  C. Tanner.  Epidemiology of Parkinson’s Disease , 1992, Neurologic Clinics.

[43]  J. Cummings,et al.  Depression and Parkinson's disease: a review. , 1992, The American journal of psychiatry.

[44]  G Vassart,et al.  Molecular cloning of a human cannabinoid receptor which is also expressed in testis. , 1991, The Biochemical journal.

[45]  T. Bonner,et al.  Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. , 1991, The New biologist.

[46]  K. Lesch,et al.  Zur Serotonin-Hypothese der Depression , 1990 .

[47]  M. Herkenham,et al.  The cannabinoid receptor: biochemical, anatomical and behavioral characterization , 1990, Trends in Neurosciences.

[48]  K. Lesch,et al.  [The serotonin hypothesis of depression]. , 1990, Fortschritte der Neurologie-Psychiatrie.

[49]  J. Krystal,et al.  Psychopharmacology: The Third Generation of Progress , 1989, The Yale Journal of Biology and Medicine.

[50]  A. Howlett,et al.  Determination and characterization of a cannabinoid receptor in rat brain. , 1988, Molecular pharmacology.

[51]  G. Paulson,et al.  Relationship of motor symptoms, intellectual impairment, and depression in Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[52]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .

[53]  E. Tolosa,et al.  Parkinson's disease with depression , 1986, Neurology.

[54]  R. Mayeux.  Behavioral manifestations of movement disorders. Parkinson's and Huntington's disease. , 1984, Neurologic clinics.

[55]  A. Robins,et al.  CANNABIS-ASSOCIATED PSYCHOSIS WITH HYPOMANIC FEATURES , 1982, The Lancet.

[56]  R. Mayeux,et al.  Depression, intellectual impairment, and Parkinson disease , 1981, Neurology.

[57]  S. Snyder,et al.  Cannabinoids: influence on neurotransmitter uptake in rat brain synaptosomes. , 1975, The Journal of pharmacology and experimental therapeutics.

[58]  R. Albertini,et al.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. , 1968, Lancet.

[59]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.